Skip to content
Screener

Bioventus BVS Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$8.7M-6.5%
Enovis logo
EnovisENOV
$2.1M-24.3%
Medtronic logo
MedtronicMDT
——

Other financials

Income statement

See full
Revenue$153.2M+3.8%
Gross profit$105.7M+3.5%
Operating income$19.1M+4.1%
Net income$33.4M+348%
EPS (diluted)$0.47+327%

Balance sheet

See full
Cash & equivalents$29.5M-10.5%
Total debt$263.7M-26.9%
Total equity$228.3M+41.6%
Total assets$673.3M-4.7%

Cash flow

See full
Operating cash flow$19.9M-23.4%
CapEx$960.0K+40.6%
Free cash flow$18.9M-25.1%

Valuation

See full
Market cap$1.19B+156%
Enterprise value$1.42B+79.7%
P/E21.8×—
P/S2×+1.2×

Profitability

See full
Gross margin68.7%+1.1pp
Operating margin10%—
Net margin9.4%+9.2pp
FCF margin16.2%+10.2pp

Returns & leverage

See full
Return on equity28%+27.5pp
Debt / equity1.2×-1.1×
Current ratio1.7×+0.2×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Bioventus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:43 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001665988-26-000042
Line itemJune 27, 2026December 31, 2025
Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of June 27, 2026 and December 31, 20251616
Additional paid-in capital527,925520,851
Accumulated deficit(298,375)(334,929)
Accumulated other comprehensive loss(1,328)(1,900)
Total stockholders’ equity attributable to Bioventus Inc.228,306184,105
Noncontrolling interest49,10644,342
Total stockholders’ equity277,412228,447
Total liabilities and stockholders’ equity$673,346$683,559

Item 1. Financial Statements (Unaudited)

FAQ

What is Bioventus's noncontrolling interests in subsidiaries?
Bioventus (BVS) reported noncontrolling interests in subsidiaries of $49.11M in Q2 2026.
How has Bioventus's noncontrolling interests in subsidiaries changed year-over-year?
Bioventus's noncontrolling interests in subsidiaries increased by 22.6% year-over-year, from $40.06M to $49.11M.
What is the long-term trend for Bioventus's noncontrolling interests in subsidiaries?
Over 4 years (2021 to 2025), Bioventus's noncontrolling interests in subsidiaries has grown at a -25.1% compound annual growth rate (CAGR), from $140.69M to $44.34M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Bioventus's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude